The INTRICATE program has brought forward a strategic technology platform to develop assets for chronic degenerative diseases in the field of musculoskeletal disease (rheumatology, orthopaedics) and neuroscience.
Using several building blocks, such as polypeptides and game-changing biopolymers, this unique platform can generate assets with selectable biological and mechanical properties.
These assets can achieve their disease-modifying effect through direct interactions at the cellular level, or indirectly as a tuneable vehicle for combination products.